alexa Linking Histone Methylation to Active DNA Demethylation | OMICS International
ISSN: 2153-0645
Journal of Pharmacogenomics & Pharmacoproteomics

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Linking Histone Methylation to Active DNA Demethylation

Tamer Fandy*

Department of Pharmaceutical Sciences, Albany College of Pharmacy, USA

*Corresponding Author:
Tamer Fandy
Department of Pharmaceutical Sciences
Albany College of Pharmacy 261 Mountain View Rd
Colchester, VT 05446, USA
Tel: 802-735-2634
Fax: 802-654-0716
E-mail: [email protected]

Received date: June 11, 2013; Accepted date: June 11, 2013; Published date: June 15, 2013

Citation: Fandy T (2013) Linking Histone Methylation to Active DNA Demethylation. J Pharmacogenomics Pharmacoproteomics 4:e133. doi: 10.4172/2153-0645.1000e133

Copyright: © 2013 Fandy T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pharmacogenomics & Pharmacoproteomics

The role of epigenetic modifications in regulating gene expression and disease progression is continuously evolving with the vast increase in our knowledge about these modifications and their physiological function. The histone code hypothesis initially proposed by Strahl and Allis [1] indicated that different combinations of covalent histone modifications influence chromatin structure and the output of the transcription machinery. The hypothesis was further extended to link the distinct histone combinations to physiological processes like apoptosis and the description of the apoptotic histone code [2]. Histone acetylation by histone acetyltransferase (HAT) and deacetylation by histone deacetylases (HDAC) are considered the most studied histone modifications and had been the focus of intense investigation in the last two decades. Those efforts were acclaimed by the FDA approval of the HDAC inhibitors vorinostat and romidepsin for the treatment of Cutaneous T Cell Lymphoma (CTCL).The link between histone acetylation and other epigenetic modifications like DNA methylation was unclear until Bird and others [3,4] described the recruitment of HDAC repressor complex by methyl-CpG-binding proteinsto methylated cytosines on DNA. The concept of hierarchical organization of histone acetylation and DNA methylation was proposed later on and speculated that DNA methylation is dominant over histone acetylation [5,6]. Emerging clinical trials using the combination of HDAC inhibitors and DNA methyltransferase (DNMT) inhibitors embraced that concept and adopted a sequential approach of administration starting with DNMT inhibitor followed by HDAC inhibitor [7,8].

Histone lysine methylation is another histone modification that can regulatethe DNA methylation machinery. Histone lysine methylation is a dynamic process regulated by histone lysine methyltransferases (KMTs) and demethylases (KDMs) and plays an important role in tumor progression. Epigenetic readers like the inhibitor of growth protein 1 (ING1) recognize histone trimethylation on a specific lysine residue (H3K4) [9]. The ING family (ING1-5) has been an emerging putative tumor suppressor gene that binds to histones in a methylation sensitive manner through a conserved Plant Homeodomain (PHD). Recently, the role of ING1 as an adaptor for the DNA demethylation machinery was identified [10]. ING1 binding to trimethylated H3K4 recruits the growth arrest and DNA Damage protein 45a (Gadd45a). Gadd45a induces gene-specific DNA demethylation through several steps that include deamination of methylated cytosine by Activation- Induced Deaminase (AID) enzyme followed by base excision repair using the thymine DNA glycosylase MBD4 [11].

Based on such findings, it is tempting to hypothesize that the combination of lysine-specific demethylase inhibitor with DNMT inhibitor would potentiate the DNA demethylation activity of the latter and enhance the re-expression of epigenetically silenced genes. Lysine-Specific Demethylase1 (LSD1) suppresses gene expression by demethylatingmono-and dimethyl-H3K4 histone marks that are associated with active gene expression. KDM5C/Jarid1C is another transcriptional repressor lysine-specific demethylase that acts on trimethylated and dimethylated H3K4. Inhibitors of LSD1 and KDM5C could potentiate the induction of silenced genes by DNMT inhibitors. Indeed, LSD1 inhibitors as single agents were successful in re-expressing epigenetically silenced genes like CDH1 in leukemia cells and augmented apoptosis induction when combined with HDAC inhibitors in glioblastoma cells [12,13]. Although such combination suffers the common disadvantage of epigenetic agents; induction of global changes in histone and DNA methylation with consequent nonspecific gene expression changes, it may constitute a successful combination therapy for different types of cancer.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11604
  • [From(publication date):
    June-2013 - May 27, 2018]
  • Breakdown by view type
  • HTML page views : 7836
  • PDF downloads : 3768

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

genetics[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7